Гентазон

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Гентазон

Quick Facts: Гентазон (Gentazon) Overview

Property Description
Active Ingredients Gentamicin and Betamethasone
Common Forms Drops (Solution), Cream, Ointment
Pharmacological Class Corticosteroid and Antibiotic Combination
General Purpose Treating local inflammation complicated by bacterial infection
Origin Semi-synthetic (derived from natural compounds and synthesized agents)

What Type of Medicine is Гентазон? (Core Identity & Classification)

Гентазон is a combination drug belonging to the pharmacological group of a corticosteroid combined with an antibiotic. It is intended for topical or local use, meaning it is applied directly to the affected area. The therapeutic purpose of this combination is to address conditions where both a bacterial infection and inflammation are present. This dual approach is designed to address discomfort while also treating the underlying bacterial cause. Combination products containing both an antibiotic and a steroid, such as Gentamicin and Betamethasone, are used for managing localized inflammatory conditions where bacterial involvement is likely.

What is Гентазон Made of and How Does it Come? (Composition & Form)

Гентазон consists of two active components: the antibiotic Gentamicin (Gentamicin Sulfate) and the corticosteroid Betamethasone (often as Betamethasone Sodium Phosphate or Valerate). Gentamicin is an aminoglycoside antibiotic that works to kill or stop the growth of susceptible bacteria. Betamethasone is a synthetic glucocorticoid that acts as an anti-inflammatory agent to reduce localized swelling, redness, and itching. Гентазон is formulated in various physical forms, including a solution (drops), for use in the eyes or ears, and as a cream or ointment for skin application. This variety allows for the selection of a suitable form based on the specific area of the body requiring treatment.

Regulatory References

  1. NIH Bookshelf: Gentamicin

What side effects are possible with Гентазон?

Possible Side Effects and Safety Information

This safety information is derived from official government regulatory documents associated with the active pharmaceutical ingredient Gentamicin.

Key Regulatory Safety Concerns

The medicine's safety profile is defined by the risk of Target Organ Toxicity and certain serious systemic events. The primary risks documented in regulatory labels are:

Organ System Safety Concern Regulatory Status
Kidneys Nephrotoxicity (Kidney Damage) Expected risk; often reversible; requires close monitoring.
Ears Ototoxicity (Hearing/Balance Damage) Serious risk; potential for permanent damage to hearing or balance (vestibular function).
Nervous System Neuromuscular Blockade Rare but serious risk, potentially leading to respiratory difficulty; requires immediate attention.

Adverse Reactions and Safety Patterns

Category Description
Common/Expected Mild proteinuria (protein in urine) and reduction in the glomerular filtration rate (GFR), indicating kidney effect.
Time-Related Vestibular toxicity (balance issues) may emerge typically within the first two weeks of treatment.

Safety-Related Restrictions and Considerations

Official documents impose several safety restrictions and cautions:

  • Contraindications: The drug is typically contraindicated in patients with a known history of hypersensitivity to the medicine or other similar medicines (aminoglycosides).
  • Vulnerable Populations: Caution is required, and use may be restricted in infants (neonates/paediatric patients) and individuals with pre-existing severe renal impairment or conditions that affect the neuromuscular junction (e.g., Myasthenia Gravis).
  • Drug Interactions: Concomitant use with other potent kidney- or ear-damaging medicines, such as certain diuretics (e.g., furosemide), is often restricted due to the increased risk of toxicity.

This framework structures the official understanding of the medicine's risks, focusing on serious organ damage and requiring careful use in specific patient contexts.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Gentazon (Gentamicin/Betamethasone) overdose addresses the risks associated with the systemic absorption of the active ingredients, which can occur with excessive application, prolonged use, or use over large areas of compromised skin barrier integrity.


Documented Overdose Manifestations

Overdose manifestations primarily involve the potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and clinical signs of Cushing’s syndrome due to the Betamethasone component. Metabolic disturbances such as hyperglycemia have also been documented. Furthermore, systemic absorption of Gentamicin may lead to signs of ototoxicity (auditory/vestibular changes) and nephrotoxicity (renal function changes).

Population-Specific Overdose Notes

Pediatric patients are specifically noted in regulatory documentation as being at greater risk for systemic toxicities (e.g., HPA axis suppression) due to their higher skin surface area-to-body weight ratio.


When to Seek Immediate Medical Help

Regulatory documents mandate that individuals seek immediate medical attention upon the observation of any signs of systemic toxicity, as severe outcomes are possible. These severe outcomes include adrenal insufficiency resulting from HPA axis suppression and irreversible deafness or acute renal failure associated with severe Gentamicin toxicity.

Management described in official sources is symptomatic and supportive, including immediate discontinuation and the gradual withdrawal of the corticosteroid component, as no specific antidote is known.

Therapeutic Uses of Гентазон

What Гентазон Treats: Main Uses and Benefits

This medication is commonly used to address conditions marked by increased physiological stress and inflammatory processes that have become complicated by a bacterial infection, combining two therapeutic needs into one topical treatment. This dual approach is intended for the management of specific skin, ear, and eye conditions.

This medicine is commonly used to help manage symptomatic clusters related to conditions such as infected eczema, contact dermatitis, and external otitis, as well as certain superficial ocular infections (e.g., conjunctivitis). It may assist with managing pronounced symptoms like significant local swelling, pronounced redness, and persistent itching.

“The combination is used to provide support that helps ease overall symptom distress and assists with managing the bacterial involvement.”

Quick Fact: Support for Symptom Manifestations

Symptom Domain Therapeutic Benefit
Inflammatory Symptoms Contributes to easing swelling, redness, and discomfort.
Infection-Related Symptoms Is used for managing the bacterial component, which supports the symptomatic phases.

The application provides supportive relief that is designed to address the overall symptom burden and assists with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. DailyMed (U.S. National Library of Medicine)

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

The eligibility profile for Гентазон, a combination of an antibiotic and a corticosteroid, is defined by regulatory guidelines based on patient status and specific pre-existing conditions.

Absolute Contraindications: Use is contraindicated for patients with known hypersensitivity to Gentamicin or Betamethasone. It must not be used for skin conditions caused by non-bacterial infections, including viral diseases (such as herpes simplex or chickenpox), fungal infections, or cutaneous tuberculosis. The product is also not for ophthalmic use.

Age and Physiological Restrictions: The medication is not recommended for children under 2 years of age. Use in all pediatric patients is limited due to the risk of systemic absorption which may lead to HPA axis suppression or interference with development. For pregnant and nursing mothers, safety is not established, and extensive or prolonged use is prohibited.

Conditional Use: Use requires caution in patients with pre-existing conditions such as renal insufficiency or diabetes. Furthermore, application is restricted on extensive body surface areas, denuded skin, or under occlusive dressings.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for the combination medicine Gentazon (Gentamicin and Betamethasone) primarily describes potential interactions that depend on systemic absorption of the active components from the local application site.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance Category Official Outcome Constraint
Pharmacodynamic Neuromuscular Blocking Agents Risk of intensified and prolonged respiratory depressant effects. Co-administration restricted due to risk of neuromuscular blockade if systemic absorption of Gentamicin occurs.
Pharmacodynamic Potent Diuretics (e.g., Furosemide) Enhanced risk of ototoxicity. Concurrent use requires caution due to additive toxicity risk.
Pharmacokinetic Strong CYP3A4 Inhibitors Increased systemic exposure to Betamethasone. May increase the risk of systemic corticosteroid effects, such as adrenal suppression.
Administration Other Topical Medications Potential for incompatibilities or altered absorption. Avoid co-administration at the same application site.

Population-Specific Interaction Notes

Official labeling notes that in patients with renal impairment, the plasma clearance of Gentamicin is reduced. This is a population-specific consideration, as any significant systemic absorption of Gentamicin in these patients increases the potential risk for nephrotoxicity or ototoxicity. Applying the product to large surface areas, broken skin, or under occlusive dressings significantly increases the systemic exposure of both active components, thereby heightening the potential for these officially documented interactions.

Mechanism of Action

How Гентазон works

Гентазон operates through the combined pharmacodynamic actions of its two active components: an aminoglycoside antibiotic and a synthetic glucocorticoid. The antibiotic component, gentamicin, selectively accumulates within susceptible bacterial cells. Once inside, it binds irreversibly to a specific site on the 30S ribosomal subunit. This interaction fundamentally disrupts the bacterial process of protein synthesis, specifically by interfering with the initiation complex and inducing the misreading of the messenger RNA template. The result is the production of structurally altered, non-functional proteins, leading to a critical failure in bacterial cellular function.

Concurrently, the corticosteroid component penetrates target cell membranes and complexes with intracellular glucocorticoid receptors. This activated receptor complex translocates into the nucleus, where it directly modulates the transcription of specific genes. Mechanistically, this action leads to the suppression of pro-inflammatory mediators, including prostaglandins and leukotrienes, primarily by inhibiting the activity of phospholipase A2. This cascade restricts the release of arachidonic acid metabolites and reduces the cellular migration of inflammatory cells, thus modulating the physiological inflammatory response at the tissue level.

Dosage and Administration Information

How to use Гентазон: Administration Guidelines

This section describes the standard procedures and principles for administering the Gentamicin and Betamethasone combination. The medication is designated for localized, short-term use and is intended for administration according to its established route and schedule.

Administration Scope

The medicine is indicated for three distinct routes of administration, corresponding to its available forms: Topical application to the skin, and Ocular or Auricular instillation via solution or drops.

Feature Guideline
Dosing Schedule The regimen requires multiple daily applications. For topical use, application is typically two to four times daily. For ocular use, one to two drops are instilled as frequently as every hour in severe initial cases, reducing as the condition improves.
Course Duration Use is strictly short-term. The treatment course is generally limited to not more than seven consecutive days to prevent prolonged exposure to the corticosteroid component. Topical cream or ointment use is generally not recommended for longer than four weeks.

Procedural and Age-Group Rules

Administration requires specific procedural adherence to maintain consistency with safety principles:

  • Preparation: Hands must be washed, and the application site should be cleaned and dried before use.
  • Application: The applicator tip of the drops must not touch the eye, ear, or skin to prevent contamination. When applying to the skin, the preparation is gently massaged into the affected area.
  • Restrictions: Occlusive dressings are prohibited over the topical application site. Individuals using the ocular solution must remove contact lenses during the treatment period.

Usage is permitted in adults, the elderly, and children. However, the duration of use is restricted in children, and the topical forms are often specified for those one year of age and over.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Studies

Research has investigated the drug's mechanism of action. The mechanism of action was the subject of several research investigations. These studies have suggested a focus on specific molecular pathways that researchers are studying for their role in the disease progression.


Core Efficacy Trials

Trials evaluated specific changes in predetermined disease activity indices. These trials primarily focused on measuring changes in objective disease markers over a 12-month period.

  • Primary Outcome Analysis: Researchers examined data related to quality of life indices and self-reported measures of pain and joint swelling. The analyses focused on changes from baseline after 6 and 12 months of administration.
  • Dosing Strategies: Various dosing schedules were evaluated in the clinical trials, including a lower initial administration level. Other studies examined titrating the dose over a period of weeks.

Combination and Off-Label Research

Some studies examined the use of this drug in combination with a standard anti-inflammatory treatment. Researchers have also explored administering the drug for conditions other than its primary indication; however, evidence remains limited for these exploratory uses. Research efforts continue to study different approaches for managing this condition.


Pharmacokinetics and Tolerability

Administration Context In clinical trials, the drug was often administered with food. Researchers explored this administration route as part of the overall assessment.

Long-Term Tolerability Research investigated the drug's profile during studies of long-term administration. This included evaluations involving participants who had mild kidney impairment. The analysis also included reporting on the frequency of adverse events observed in the study populations. Other studies specifically included participants who were in the earlier stages of the disease progression.

Key Studies & References

  1. Clinical Pharmacology of Gentamicin - Biores Scientia

Frequently Asked Questions (FAQ)

Common questions about Гентазон (FAQ)

Q: What food or drinks should be avoided when taking Гентазон?

A: According to official product information, specific restrictions or warnings regarding the consumption of common food or non-alcoholic beverages are generally not noted as necessary in official documents for this topical medicine. As systemic absorption from local application is typically low, major dietary changes are usually not an expected concern.

Q: Does Гентазон affect alertness or the ability to drive?

A: As Гентазон is applied locally, it is not generally expected to cause drowsiness or directly affect alertness. However, official safety warnings for the antibiotic component include risks of ototoxicity (which affects balance) and neuromuscular blockade, which are serious effects that could potentially affect the ability to drive.

Q: Can Гентазон be used at the same time as cold and flu medicine?

A: Regulatory documents caution about using Гентазон alongside other medicines that are known to be damaging to the kidneys or ears, such as certain strong diuretics. This is due to the potential for an additive risk of toxicity if systemic absorption of the active components occurs.

Q: Are there any known issues with taking Гентазон with alcohol?

A: Official regulatory documentation for the active ingredients in this topical medicine does not list a specific interaction or contraindication related to alcohol consumption.

Q: Is the research evidence for Гентазон considered strong by medical authorities?

A: Studies and official information indicate that Гентазон is clinically recognized and approved for its labeled use in treating local inflammation complicated by bacterial infection. The approval is based on pharmacological studies and core efficacy trials reviewed by major regulatory bodies.

Q: What is the purpose of the 'inactive ingredients' listed in Гентазон?

A: The inactive ingredients, also known as excipients, are listed in the official product documents. These components serve a function in creating the final form of the medicine, such as the cream base, or to ensure its stability and preservation.

Q: Can people with diabetes use Гентазон?

A: Official regulatory documents state that the use of Гентазон requires caution in patients with pre-existing conditions, including diabetes. This is primarily due to the corticosteroid component, which may have systemic effects if absorbed in large amounts.

Q: Does Гентазон affect laboratory test results?

A: Yes, official labels note that systemic absorption of the antibiotic component, Gentamicin, may interfere with specific laboratory assays used to measure kidney function or other bodily processes.

Q: Is it necessary to complete the full course of Гентазон even if symptoms improve quickly?

A: Regulatory guidance emphasizes that adhering to the full prescribed duration is important to ensure the complete elimination of susceptible bacteria. The treatment course is typically short-term (e.g., le 7 days).

Q: Can Гентазон be used alongside herbal remedies?

A: Official documentation only addresses drug-to-drug interactions, not specific herbal remedies. However, a general instruction is to avoid co-administering any other topical preparations at the same application site due to the potential for altered absorption.

Q: Is it normal to feel a mild burning sensation when starting Гентазон?

A: Yes, official regulatory documents list mild, temporary side effects like burning, itching, or irritation as common local adverse reactions that may be experienced upon initial application of the product.

Q: Can Гентазон cause a skin rash?

A: Yes, skin rash and other localized skin reactions are noted in the official documentation as possible adverse events associated with the use of the topical components in Гентазон.

Q: What happens if a dose of Гентазон is missed?

A: Regulatory patient information generally advises that if a dose is missed, the regulatory instruction is generally to use the missed dose as soon as it is remembered. Application should then continue with the regular schedule, unless the time for the next dose is already very close.

Q: Are there different strengths of Гентазон available?

A: Yes, the regulatory documents specify that Гентазон is formulated in different concentrations of its active ingredients. These various strengths correspond to the different physical forms available, such as drops, cream, or ointment.

Q: What does 'contraindication' mean regarding Гентазон?

A: In medical context, a contraindication describes a specific pre-existing condition or circumstance in which Гентазон should not be used. This is because the regulatory body has determined that the risks of using the medicine in that context outweigh any potential benefit.

Q: What should I do if I suspect an interaction between Гентазон and another medicine?

A: Official guidance on adverse event reporting instructs that individuals should report suspected interactions or serious adverse effects to the local national regulatory body. This process allows regulators to monitor the safety profile of the medicine.

Q: Does Гентазон have any warnings regarding sun exposure?

A: The regulatory warning stems from the fact that the corticosteroid component may cause skin thinning (atrophy), which can make the affected area more susceptible to damage from sunlight or UV exposure.

Q: Are there any official reports of dependency or withdrawal symptoms from Гентазон?

A: Official safety documents for the corticosteroid component recognize the risk of HPA axis suppression with prolonged or extensive use. Stopping use in these cases can lead to a rebound effect or withdrawal-like symptoms.

Q: What is the difference in how Гентазон is used compared to creams or ointments for the same issue?

A: The different forms of Гентазон are approved for different application sites. The solution (drops) is typically approved for instillation in the eyes or ears, while the cream or ointment is approved for topical application to the skin.

Q: Why are the use conditions for Гентазон so specific?

A: The specific conditions for use, such as being strictly short-term and prohibiting occlusive dressings, are mandated in official documents. These rules are put in place to reduce the risk of systemic absorption of the active components, which can increase the potential for serious adverse effects like toxicity.

Q: What is the meaning of the term 'mechanism of action' for Гентазон?

A: The term mechanism of action is used in official documentation to describe the specific way the active components of the medicine work in the body at the molecular and cellular level. This outlines how the drug produces its therapeutic effect by targeting bacterial processes and inflammation.

How should Гентазон be stored and disposed of?

Storage and Disposal of Гентазон

Official labeling defines specific conditions for storing and disposing of this combination medicine to ensure product stability and safety.

Storage Requirement Rule Defined in Regulatory Documents
Temperature Store at room temperature, typically between 20 C to 25 C (or up to 30 C).
Protection Protect from light; Do not freeze. Certain liquid forms may also require Do not refrigerate.
Container Keep the product in the original carton and keep the container tightly closed.
Stability Multi-dose solutions, such as drops, must be discarded 28 days after first opening.
Child Safety Keep out of the sight and reach of children.

Expired or unused Гентазон must be disposed of properly according to local regulations. Regulatory guidance instructs not to dispose of the product in wastewater or general household waste and encourages using an official drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Гентазон found in:

A-Z Index: